Mobile-phone text messaging to promote ideal cardiovascular health in women
- PMID: 36759011
- PMCID: PMC9923351
- DOI: 10.1136/openhrt-2022-002214
Mobile-phone text messaging to promote ideal cardiovascular health in women
Abstract
Objective: Ideal cardiovascular health (CVH) was developed to promote CVH as a key component of primordial prevention. Mobile short message service (SMS) is useful for improving health behaviours. We aim to test the effectiveness of SMS intervention in women to improve CVH.
Methods: In a single-blinded, randomised, controlled study, 620 women, aged 35-70 years, without cardiovascular disease, were enrolled in SMS intervention versus no SMS. CVH metrics by self-report, and biochemical laboratory, anthropometric and blood pressure measurements were collected during home visits at baseline and 9 months. Women were categorised as having poor (0-2), intermediate (3-4) or ideal (5-7) CVH according to the number of ideal CVH metrics. Participants were randomised 1:1 to SMS intervention versus control. SMS was sent every 5-6 days for 9 months. The primary outcome was the difference in the proportion of women with ideal CVH between SMS and control groups at 9 months. Rates of intermediate CVH, poor CVH and each of the seven ideal CV health metrics at 9 months were key secondary endpoints.
Results: At 9 months, there was no significant difference between groups for the primary outcome (16.3% at baseline and 13.3% at 9 months, and 10.1% and 11.1%, in SMS and control groups, respectively, adjusted RR 1.0; 95% CI 0.6 to 1.6). Similarly, there were no significant differences between groups for the key secondary endpoints. SMS had an acceptance rate of 94.9%.
Conclusions: Behavioural SMS intervention did not improve rates of ideal CVH in women, despite being feasible and well received.
Trial registration number: 6377.
Keywords: Global Health; Outcome Assessment, Health Care; RISK FACTORS.
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: MA has served on an advisory board for AstraZeneca, Bayer, Novo Nordisk, Boehringer, Tecnofarma, Axon Pharma, Novartis and has received fees for speaking from AstraZeneca, Boehringer Ingelheim, Bayer, Novo Nordisk, Tecnofarma, TEVA Pharmaceuticals, Abbott, Axon Pharma, Elli Lilly. PV has served on advisory boards for Axon Pharma, Novo Nordisk, Boehringer Ingelheim, Novartis, and has received fees for speaking from: Boehringer Ingelheim, AstraZeneca Novo Nordisk, Axon Pharma, Abbott, Bayer and Tecnofarma, Organon, Teva Pharmaceuticals and fees for being the principal investigator for the following Clinical Studies: Horizon (Novartis)/ Victorion Prevent (Novartis).
References
-
- Ministerio de Salud, Departamento de Epidemiología, División de Planificación Sanitaria . Encuesta nacional de salud 2016-2017. Primeros resultados. 2017. Available: https://www.minsal.cl/wp-content/uploads/2017/11/ENS-2016-17_PRIMEROS-RE...
-
- Margozzini P, Passi Á. Encuesta nacional de salud, ENS 2016-2017: un aporte a la planificación sanitaria Y políticas públicas en Chile. ARS Med 2018;43:30–4. 10.11565/arsmed.v43i1.1354 - DOI
-
- Nazzal C, Alonso FT. Las mujeres jóvenes en Chile tienen elevado riesgo de muerte intrahospitalaria POR infarto de miocardio. Revista Española de Cardiología 2013;66:104–9. 10.1016/j.recesp.2012.07.015 - DOI
-
- Instituto Nacional De Estadísticas, Subdepartamento de Demografía y Vitales, Departamento de Informática, et al. Estadísticas Vitales. Informe Anual 2016. Available: https://www.ine.cl/docs/default-source/demogr%C3%A1ficas-y-vitales/vital...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources